| In vitro: |
| Biol Pharm Bull. 1994 Mar;17(3):460-2. | | Inhibitory effect of karounidiol on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion.[Pubmed: 8019519] |
METHODS AND RESULTS:
Karounidiol [D:C-Friedo-oleana-7,9(11)-diene-3 alpha,29-diol] and 7-oxodihydrokarounidiol [7-oxo-D:C-friedo-olean-8-ene-3 alpha,29-diol], isolated from the seeds of Trichosanthes kirilowii, were examined for the effect on 12-O-tetradecanoylphorbol-13-acetate (TPA, 1 microgram/ear)-induced inflammation, following application of this tumor-promoting agent, to the ears of mice. Both compounds inhibited the inflammatory activity induced by TPA and the 50% inhibitory dose for TPA-induced inflammation was 0.3 and 0.4 mg/ear, respectively. Furthermore, at 2 mumol/mouse, karounidiol markedly suppressed the promoting effect of TPA (1 microgram/mouse) on skin tumor formation in mice following initiation with 7,12-dimethylbenz[a]anthracene (50 micrograms/mouse). | | Cancer Lett. 2001 Nov 8;173(1):9-14. | | Anti-tumor promoting effects of multiflorane-type triterpenoids and cytotoxic activity of karounidiol against human cancer cell lines.[Pubmed: 11578803] |
METHODS AND RESULTS:
Forty-nine multiflorane-type triterpenoids consisting of 11 compounds isolated from the seeds of Trichosanthes kirilowii (Cucurbitaceae) and 38 of their derivatives have been evaluated for their inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation induced by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate in Raji cells as a primary screening test for anti-tumor promoters.
CONCLUSIONS:
All of the compounds tested showed an inhibitory effect against EBV-EA activation, and among which 43 were revealed to possess remarkable activity with potencies either comparable to or stronger than that of glycyrrhetic acid, a known natural anti-tumor promoter.
Their structure-activity relationship is discussed. Evaluation of the cytotoxic activity of Karounidiol (27) against human cancer cell lines exhibited cytotoxicity especially against a human renal cancer. |
|
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)
